Pharmacol Res. 2026 Nov 14:109747. doi: 10.1016/j.phrs.2026.109747. Online ahead of print.
ABSTRACT
Vascular calcification, an important pathological process of cardiovascular remodeling, is primarily driven by the transition of vascular smooth muscle cells from contractile to osteogenic phenotype. Protein inhibitor of activated STAT1 (PIAS1) is closely associated with diabetes and vascular diseases, but its role and underlying mechanisms in the progression of diabetic vascular calcification (DVC) remain unclear. Herein, we investigated the role of PIAS1 in DVC by genetic modulation and explored its molecular mechanisms by transcriptomics and co-immunoprecipitation with mass spectrometry (Co-IP-MS). We demonstrate that PIAS1 expression is downregulated in both in vitro and in vivo DVC models; furthermore, PIAS1 overexpression alleviates DVC, whereas PIAS1 knockout exacerbates it. Mechanistically, Co-IP-MS analysis reveals an interaction between PIAS1 and voltage-dependent anion channel 1 (VDAC1), which enhances the SUMOylation of VDAC1 while inhibiting its oligomerization. PIAS1 also reduces the binding between NLR family member X1 (NLRX1) and VDAC1, ultimately attenuating mitochondrial DNA leakage into the cytoplasm. More importantly, we find that Ginsenoside Ro is a PIAS1-targeting natural product which alleviates DVC. These findings identify PIAS1 as a novel therapeutic target for DVC and provide a new candidate for DVC prevention and treatment.
PMID:43033884 | DOI:10.1016/j.phrs.2026.109747

